Literature DB >> 19200227

Administration of donor-derived transplant acceptance-inducing cells to the recipients of renal transplants from deceased donors is technically feasible.

James A Hutchinson1, Felix Gövert, Paloma Riquelme, Jan Hinrich Bräsen, Beate G Brem-Exner, Martina Matthäi, Maren Schulze, Lutz Renders, Ulrich Kunzendorf, Edward K Geissler, Fred Fändrich.   

Abstract

Patient KW, a 36-yr-old male renal transplant recipient, received transplant acceptance-inducing cells (TAICs) as an adjunct immunosuppressive therapy. In the weeks post-transplantation, the patient's conventional immunosuppressive treatment was gradually minimized, such that, from the 21st wk post-transplantation onwards, the patient was stably maintained on tacrolimus monotherapy. Treatment with TAICs was without complication, both at the time of administration and in the four-yr follow-up period. It is concluded that the production and administration of TAICs to recipients of kidney transplants from deceased donors is technically feasible.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19200227     DOI: 10.1111/j.1399-0012.2008.00953.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  8 in total

Review 1.  Tolerance in clinical transplantation: progress, challenge or just a dream?

Authors:  Fred Fändrich
Journal:  Langenbecks Arch Surg       Date:  2011-03-17       Impact factor: 3.445

2.  Translating tolerogenic therapies to the clinic - where do we stand?

Authors:  Fadi Issa; Kathryn J Wood
Journal:  Front Immunol       Date:  2012-08-20       Impact factor: 7.561

3.  In question: the scientific value of preclinical safety pharmacology and toxicology studies with cell-based therapies.

Authors:  Christiane Broichhausen; Paloma Riquelme; Norbert Ahrens; Anja K Wege; Gudrun E Koehl; Hans J Schlitt; Bernhard Banas; Fred Fändrich; Edward K Geissler; James A Hutchinson
Journal:  Mol Ther Methods Clin Dev       Date:  2014-07-16       Impact factor: 6.698

4.  Pre-transplant infusion of donor leukocytes treated with extracorporeal photochemotherapy induces immune hypo-responsiveness and long-term allograft survival in murine models.

Authors:  Jennifer Schneiderman; Longhui Qiu; Xin Yi Yeap; Xin Kang; Feibo Zheng; Junsheng Ye; Yan Xie; Jiao-Jing Wang; Yuvaraj Sambandam; James Mathew; Lin Li; Joseph Leventhal; Richard L Edelson; Zheng Jenny Zhang
Journal:  Sci Rep       Date:  2022-05-04       Impact factor: 4.996

5.  Alternative approaches to myeloid suppressor cell therapy in transplantation: comparing regulatory macrophages to tolerogenic DCs and MDSCs.

Authors:  Paloma Riquelme; Edward K Geissler; James A Hutchinson
Journal:  Transplant Res       Date:  2012-09-28

Review 6.  Clinical Use of Tolerogenic Dendritic Cells-Harmonization Approach in European Collaborative Effort.

Authors:  Anja Ten Brinke; Catharien M U Hilkens; Nathalie Cools; Edward K Geissler; James A Hutchinson; Giovanna Lombardi; Phillip Lord; Birgit Sawitzki; Piotr Trzonkowski; S Marieke Van Ham; Eva M Martinez-Caceres
Journal:  Mediators Inflamm       Date:  2015-12-24       Impact factor: 4.711

Review 7.  Contemporary Strategies and Barriers to Transplantation Tolerance.

Authors:  Brian Ezekian; Paul M Schroder; Kyle Freischlag; Janghoon Yoon; Jean Kwun; Stuart J Knechtle
Journal:  Transplantation       Date:  2018-08       Impact factor: 4.939

Review 8.  Tolerising cellular therapies: what is their promise for autoimmune disease?

Authors:  Chijioke H Mosanya; John D Isaacs
Journal:  Ann Rheum Dis       Date:  2018-11-02       Impact factor: 19.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.